FMP
Rocket Pharmaceuticals Shares Jump 40% on Alignment with FDA
Sep 13, 2023 5:15 PM - Davit Kirakosyan(Last modified: Dec 19, 2023 6:49 PM)
Image credit: FMP
Rocket Pharmaceuticals (NASDAQ:RCKT) shares jumped more than 40% intra-day today after the company announced an agreement with the U.S. FDA regarding the Phase 2 trial of RP-A501.
This trial targets Danon disease, a life-threatening inherited cardiomyopathy. The CEO of Rocket Pharmaceuticals, Gaurav Shah, expressed confidence that this agreement represents a significant step toward efficiently and swiftly providing potential therapy to Danon Disease patients, potentially avoiding the need for heart transplantation or the risk of death.
Other Blogs
May 14, 2024 11:41 AM - Sanzhi Kobzhan
The easiest way to calculate stock’s target price and why the target price is important.
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 27, 2024 3:30 PM - Rajnish Katharotiya
The best 5 GPU stocks other than NVDA
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...
Jun 6, 2024 2:47 AM - Parth Sanghvi
ROE vs ROA: Which Metric is More Important for Investors?
ROE vs. ROA: Which Metric is More Important for Investors? When evaluating a company's financial performance, investors often rely on various metrics to gauge profitability and efficiency. Two commonly discussed metrics are Return on Equity (ROE) and Return on Assets (ROA). Understanding the diff...
